Opdivo

Another blow for BMS in first-line NSCLC as it pulls EU filing

Opdivo/Yervoy combination is still under review with the FDA. Bristol-Myers Squibb has decided to abandon its marketing application in the EU for its Opdivo/Yervoy checkpoint inhibitor combination in ... trial, which evaluated Opdivo/Yervoy given

Roche files Tecentriq/Avastin combo in liver cancer

Bristol-Myers Squibb’s Opdivo (nivolumab).

Newly-listed BioNTech buys Neon to boost cell therapy assets

who are not responding to treatment with checkpoint inhibitor drugs like Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck &Co’s Keytruda (pembrolizumab).

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

A verdict is expected to be delivered by 15 May. Bristol-Myers Squibb’s marathon to get approval for its immuno-oncology drug Opdivo in first-line non-small cell lung ... The FDA has started a priority review of PD-1 inhibitor Opdivo (nivolumab) in

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

A combination trial of Rubraca plus Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) – called CheckMate 9KD – is also ongoing with initial results due later this year.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]